tradingkey.logo
搜索

Myriad Genetics Inc

MYGN
添加自选
5.990USD
-0.010-0.17%
收盘 07/02, 13:00美东报价延迟15分钟
565.46M总市值
亏损市盈率 TTM

Myriad Genetics Inc

5.990
-0.010-0.17%
查看详细走势图
TradingKey 图表
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-0.17%

5天

+1.87%

1月

+27.72%

6月

-2.44%

今年开始到现在

-2.60%

1年

+6.96%

关键数据
6.050今开
6.120最高
1.32M成交量
亏损市盈率 TTM
40.24市盈率动
--股息TTM
1.40%换手率
6.000昨收
5.920最低
5.73M成交额
亏损市盈率静
1.68市净率
0.00%股息率 TTM
-47.61%ROA
8.59052周最高
0.95量比
-127.30M净利润
94.40M总股本
-4.3142每股收益TTM
1.77Beta
-76.73%ROE
3.53052周最低
3.33%振幅
68.66%毛利率
565.46M总市值
7.15回报/风险
3.91%风险率

TradingKey Myriad Genetics Inc股票评分

单位: USD 更新时间: 2026-07-02

操作建议

Myriad Genetics Inc当前公司基本面数据相对健康,增长潜力较大。当前估值合理,在医疗设备与耗材行业排名85/204位。机构持股占比非常高,近一月多位分析师给出公司评级为持有。最高目标价6.50。中期看,股价处于上升通道。近一个月,市场表现很强,技术面和基本面综合得分较高,很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。

Myriad Genetics Inc评分

相关信息

行业排名
85 / 204
全市场排名
196 / 4565
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
中性

Myriad Genetics Inc亮点

亮点风险
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
利润高增长
公司净利润处于行业前列,最新年度总收入824.50M美元
估值高估
公司最新PE估值-1.39,处于3年历史高位
机构减仓
最新机构持股102.95M股,环比减少6.61%

分析师目标

根据 10 位分析师
持有
评级
6.500
目标均价
+8.33%
涨幅空间

Myriad Genetics Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Myriad Genetics Inc简介

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
公司代码MYGN
公司Myriad Genetics Inc
CEORaha (Samraat S)
网址https://myriad.com/

常见问题

Myriad Genetics Inc(MYGN)的当前股价是多少?

Myriad Genetics Inc(MYGN)的当前股价是 5.99。

Myriad Genetics Inc的股票代码是什么?

Myriad Genetics Inc的股票代码是MYGN。

Myriad Genetics Inc股票的52周最高点是多少?

Myriad Genetics Inc股票的52周最高点是8.59。

Myriad Genetics Inc股票的52周最低点是多少?

Myriad Genetics Inc股票的52周最低点是3.53。

Myriad Genetics Inc的市值是多少?

Myriad Genetics Inc的市值是565.46M。

现在Myriad Genetics Inc(MYGN)的股票是买入、持有还是卖出?

根据分析师评级,Myriad Genetics Inc(MYGN)的总体评级为signal_hold,目标价格为6.50。

Myriad Genetics Inc(MYGN)股票的每股收益(EPS TTM)是多少

Myriad Genetics Inc(MYGN)股票的每股收益(EPS TTM)是-3.95。